// App-Quantinova.ai

BSH2020‐PO‐081 : Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL)

Researchers

Presenter

  • L. H. Sehn

Principal Investigators

  • A. McMillan

  • M. J. Matasar

  • C. R. Flowers

  • M. Kamdar

  • M. Hertzberg

  • S. Assouline

  • T. M. Kim

  • W. S. Kim

  • M. Ozcan

  • B. Croft

  • A. F. Herrera

  • J. Hirata

  • J. Cheng

  • G. Ku

Medical Centers

  • BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada, Vancouver, Canada

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The Winship Cancer Institute of Emory University, Atlanta, GAEmory University, Atlanta, GA

  • Univeristy of Colorado, Denver, CO

  • Prince of Wales Hospital and University of New South Wales,Sydney, NSW,Australie

  • Jewish General Hospital, Montreal, QC, Canada

  • Chonnam National University Hospital

  • Sungkyunkwan univ Samsung medical center, Seoul, Korea, Republic Of

  • Ankara University, Ankara, Turkey

  • Genentech, Inc., South San Francisico, CA

  • City of Hope National Medical Center, Duarte, CA

  • Genentech, Inc., South San Francisico, CA

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Genentech, Inc., South San Francisico, CA

Locations

  • Canada

  • United Kingdom

  • United States

  • Australia

  • Turkey

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

  • Peripheral Nervous System

Disease

  • Diffuse large B-cell lymphoma

  • Peripheral neuropathy

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Polatuzumab vedotin

  • Bendamustine

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • I

Study Id's

  • NCT02257567

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved